Deeann Wallis
Overview
Explore the profile of Deeann Wallis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
949
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fay C, Zunica E, Awad E, Bradley W, Church C, Liu J, et al.
Sci Rep
. 2025 Jan;
15(1):3883.
PMID: 39890807
In efforts to evaluate potential biomarkers and drug targets for Neurofibromatosis Type I (NF1) we utilized affinity mass spectrometry and global proteomics to investigate how variation within and loss of...
2.
Chen Y, Fu Y, Koczkowska M, Callens T, Gomes A, Liu J, et al.
Cancers (Basel)
. 2024 Jul;
16(13).
PMID: 39001468
Neurofibromatosis type 1 (NF1) is an autosomal dominant neurocutaneous disorder caused by loss-of-function variants in the gene. As of 20 November 2023, over 5000 distinct pathogenic or likely pathogenic variants...
3.
Church C, Fay C, Kriukov E, Liu H, Cannon A, Baldwin L, et al.
Acta Neuropathol Commun
. 2024 Jun;
12(1):102.
PMID: 38907342
Neurofibromatosis Type 1 (NF1) is caused by loss of function variants in the NF1 gene. Most patients with NF1 develop skin lesions called cutaneous neurofibromas (cNFs). Currently the only approved...
4.
Staedtke V, Anstett K, Bedwell D, Giovannini M, Keeling K, Kesterson R, et al.
Clin Trials
. 2023 Nov;
21(1):51-66.
PMID: 37937606
Numerous successful gene-targeted therapies are arising for the treatment of a variety of rare diseases. At the same time, current treatment options for neurofibromatosis 1 and schwannomatosis are limited and...
5.
Leier A, Moore M, Liu H, Daniel M, Hyde A, Messiaen L, et al.
Mol Ther Nucleic Acids
. 2022 Apr;
28:261-278.
PMID: 35433111
We investigated the feasibility of utilizing an exon-skipping approach as a genotype-dependent therapeutic for neurofibromatosis type 1 (NF1) by determining which exons might be skipped while maintaining neurofibromin protein expression...
6.
Awad E, Moore M, Liu H, Ciszewski L, Lambert L, Korf B, et al.
J Pers Med
. 2021 Dec;
11(12.
PMID: 34945792
Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder with almost 3000 different disease-causing variants within the gene identified. Up to 44% of these variants cause splicing errors to...
7.
Long A, Crouse A, Kesterson R, Might M, Wallis D
Am J Med Genet B Neuropsychiatr Genet
. 2021 Dec;
189(1-2):37-47.
PMID: 34889524
Variants within the Neurotrophic Tyrosine Kinase Receptor Type 2 (NTRK2) gene have been discovered to play a role in developmental and epileptic encephalopathies, a group of debilitating conditions for which...
8.
Long A, Liu H, Liu J, Daniel M, Bedwell D, Korf B, et al.
Hum Mutat
. 2021 Oct;
43(1):30-41.
PMID: 34694046
We have created a panel of 29 NF1 variant complementary DNAs (cDNAs) representing missense variants, many with clinically relevant phenotypes, in-frame deletions, splice variants, and nonsense variants. We have determined...
9.
Wallis D, Stemmer-Rachamimov A, Adsit S, Korf B, Pichard D, Blakeley J, et al.
Neurology
. 2021 Jul;
97(7 Suppl 1):S42-S49.
PMID: 34230199
Objective: To summarize existing biomarker data for cutaneous neurofibroma (cNF) and to inform the incorporation of biomarkers into clinical trial design for cNFs. Methods: The cNF working group, a subgroup...
10.
Leier A, Bedwell D, Chen A, Dickson G, Keeling K, Kesterson R, et al.
Mol Ther Nucleic Acids
. 2020 May;
20:739-753.
PMID: 32408052
Significant advances in biotechnology have led to the development of a number of different mutation-directed therapies. Some of these techniques have matured to a level that has allowed testing in...